Your browser doesn't support javascript.
loading
Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017-2019.
Byun, Seong-Eun; Kim, Hasung; Lee, Seung Yun; Kim, Sang-Min.
Afiliação
  • Byun SE; Department of Orthopaedic Surgery, CHA Bundang Medical Center, CHA University, Seongnam-si, Republic of Korea.
  • Kim H; Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Republic of Korea.
  • Lee SY; Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Republic of Korea.
  • Kim SM; Department of Orthopedic Surgery, Korea University College of Medicine, Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul, 02841, Republic of Korea. heavystone75@gmail.com.
Osteoporos Int ; 35(5): 775-783, 2024 May.
Article em En | MEDLINE | ID: mdl-38240755
ABSTRACT
With the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years.

PURPOSE:

This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years.

METHODS:

The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017-2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan-Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups.

RESULTS:

The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.61-0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group. Analysis for specific fractures showed a lower hazard of hip fracture in the SERM + VitD group (HR, 0.25; 95% CI, 0.09-0.71; p = 0.009). No difference was observed between the groups regarding mortality.

CONCLUSION:

The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Osteoporose / Osteoporose Pós-Menopausa / Fraturas por Osteoporose / Fraturas do Quadril Limite: Female / Humans Idioma: En Revista: Osteoporos Int Assunto da revista: METABOLISMO / ORTOPEDIA Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Osteoporose / Osteoporose Pós-Menopausa / Fraturas por Osteoporose / Fraturas do Quadril Limite: Female / Humans Idioma: En Revista: Osteoporos Int Assunto da revista: METABOLISMO / ORTOPEDIA Ano de publicação: 2024 Tipo de documento: Article